Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCM-16021 for Diarrhea-predominant IBS
NCT03457324Phase 3Unknown
- Start
- Nov 2018
- Primary completion
- Jun 2021
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Irritable bowel syndrome with diarrhea (IBS-D) comparing JCM-16021 Group with Placebo Group (2 arms). Primary endpoint: Global Assessment of Improvement at 16 weeks. Status: unknown.
02
Drugs
Renshu Changle
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT03457324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03457324.